Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|13|6|661-669

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.13, Iss.6, 2013-07, pp. : 661-669

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapy for Older AML Patients: The Role of Novel Agents and Allogeneic Stem Cell Transplant

By Lancet Jeffrey E. Giralt Sergio

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 1017-1025

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Current Status of Allogeneic Hematopoietic Cell Transplantation for MDS

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3215-3221

Bentham Science Publishers

Access to resources Recommend Favorite

Oral beclomethasone dipropionate: a topically active corticosteroid for the treatment of gastrointestinal graft-versus-host disease following allogeneic hematopoietic cell transplantation

By McDonald George B

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 10, 2007-10 ,pp. : 1709-1724

Informa Healthcare

Access to resources Recommend Favorite

Antifungal Agents in Hematopoietic Stem Cell Transplantation

Current Pharmaceutical Design, Vol. 14, Iss. 20, 2008-07 ,pp. : 2011-2021

Bentham Science Publishers

Access to resources Recommend Favorite

Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation

By Servais Sophie Beguin Yves Baron Frédéric

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. : 173-192

Informa Healthcare

Access to resources Recommend Favorite